Abstract |
Seventy adults in the United States with acute diarrhea who were attending classes in Guadalajara, Mexico, enrolled in a double-blind placebo-controlled treatment study of an anticholinergic drug, mepenzolate bromide (MZB). Thirty-five patients received MZB (50 mg) and 35 received placebo each taken 4 times daily for 48 hours. No significant difference was detected between the MZB- and placebo-treated patients in symptoms or in the frequency or character of stools. Recovery rates of 24.1% and 31% for placebo- and MZB-treated patients were similar. Despite the occurrence of anticholinergic side effects in 51% of MZB- versus 14% of placebo-treated patients (P less than 0.001), therapeutic efficacy was not detected. We do not recommend anticholinergic drugs for therapy in acute infectious diarrhea.
|
Authors | R Reves, P Bass, H L DuPont, P Sullivan, J Mendiola |
Journal | Journal of clinical gastroenterology
(J Clin Gastroenterol)
Vol. 5
Issue 3
Pg. 223-7
(Jun 1983)
ISSN: 0192-0790 [Print] United States |
PMID | 6345649
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzilates
- Parasympatholytics
- Piperidines
- mepenzolic acid
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Benzilates
(therapeutic use)
- Clinical Trials as Topic
- Diarrhea
(drug therapy)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Parasympatholytics
(therapeutic use)
- Piperidines
(therapeutic use)
- Travel
|